Sichuan Tianxinghui Pharmaceutical Technology

Sichuan Tianxinghui Pharmaceutical Technology is a clinical-stage biotechnology company based in Chengdu, China, specializing in the development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in metabolic diseases and autoimmune disorders, with a primary emphasis on gout and inflammatory conditions. Its lead candidate, TXH-1011, is a potent URAT1 inhibitor currently in Phase 2 clinical trials for the treatment of hyperuricemia and gout. Additionally, the company is advancing a pipeline of selective kinase inhibitors, including JAK1 and TYK2 inhibitors, aimed at various immunological indications. Tianxinghui leverages its internal R&D capabilities to design and optimize high-affinity molecules with improved safety and efficacy profiles.